Author:
Teliga-Czajkowska Justyna,Sienko Jacek,Jalinik Katarzyna,Derlatka Paweł,Danska-Bidzinska Anna,Czajkowski Krzysztof
Publisher
Springer International Publishing
Reference33 articles.
1. CDER/CBER (2018) U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) (2018) Guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics.
http://www.fda.gov/downloads/Drugs/.../Guidances/ucm071590.pdf
. Accessed on 15 Feb 2019
2. Chambers SK, Ivins CM, Carcangiu ML (1998) Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients. Int J Cancer 79(5):449–454
3. Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C, Nur U, Tracey E, Coory M, Hatcher J, McGahan CE, Turner D, Marrett L, Gjerstorff ML, Johannesen TB, Adolfsson J, Lambe M, Lawrence G, Meechan D, Morris EJ, Middleton R, Steward J, Richards MA (2011) Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 377(9760):127–138
4. Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ (2002) Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 134(6):1563–1571
5. Devy L, Blacher S, Grignet-Debrus C, Bajou K, Masson V, Gerard RD, Gils A, Carmeliet G, Carmeliet P, Declerck PJ, Nöel A, Foidart JM (2002) The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J 16(2):147–154
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献